Literature DB >> 10930645

Antiviral activity of NMSO3 against respiratory syncytial virus infection in vitro and in vivo.

K Kimura1, S Mori, K Tomita, K Ohno, K Takahashi, S Shigeta, M Terada.   

Abstract

NMSO3, a sulfated sialyl lipid was evaluated for its efficacy against respiratory syncytial virus (RSV) and other myxovirus infections in cell culture. The median effective concentration (50% effective concentration, EC(50)) of NMSO3 against replication of the Long strain of RSV in HEp-2 cells was 0.2 and 0.32 microM by optical ELISA and the plaque reduction method, respectively. On the other hand, the corresponding values for ribavirin were 10.5 and 11.2 microM, respectively. NMSO3 showed potent activity against other laboratory strains as well as fresh clinical isolates of RSV, and the average EC(50) was similar to that for Long strain. NMSO3 exhibited minimal cytotoxicity against HEp-2, MDCK, HMV-2 and Vero cells for which the median cytotoxic concentration (CC(50)) was more than 685 microM. The selectivity index [SI=(CC(50) for HEp-2/EC(50))] of NMSO3 for RSV exceeded 2978 and that of ribavirin was 6. The EC(50) of NMSO3 against influenza virus (FluV) A (H3N2) was 23.8 by the MTT method using HMV-2 cells, and 17.8 microM by the TCID(50) method using MDCK cells. NMSO3 did not inhibit replication of influenza B virus, parainfluenza virus type 2 and canine distemper virus at 103 microM. NMSO3 inhibited RSV infection of HEp-2 cells when it was added between 0 and 1.5 h after virus infection. By a temperature shift experiment during the period of contact between the virus and cells, NMSO3 inhibited both the binding of RSV to the cells and its penetration into the cells. Prophylactic and therapeutic efficacy of NMSO3 against RSV infection in cotton rats was examined. Intraperitoneal administration of 100 mg/kg per day of NMSO3 to cotton rats from 1 day before or 1 h after to 3 days after the RSV infection, once a day every day, decreased the RSV titer in lungs to 10(-1.26) to 10(-1.63) compared to the control rats which were infected with RSV and left untreated.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10930645     DOI: 10.1016/s0166-3542(00)00091-7

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  19 in total

1.  Anti-adenoviral effect of anti-HIV agents in vitro in serotypes inducing keratoconjunctivitis.

Authors:  Eiichi Uchio; Aki Fuchigami; Kazuaki Kadonosono; Akio Hayashi; Hiroaki Ishiko; Koki Aoki; Shigeaki Ohno
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-01-17       Impact factor: 3.117

2.  Development of liposomal nanoconstructs targeting P-selectin (CD62P)-expressing cells by using a sulfated derivative of sialic acid.

Authors:  Saotomo Itoh; Kumi Kawano; Kana Takeshita; Yoshie Maitani; Tsutomu Tsuji
Journal:  Pharm Res       Date:  2014-05-03       Impact factor: 4.200

3.  Intracytoplasmic trapping of influenza virus by a lipophilic derivative of aglycoristocetin.

Authors:  Evelien Vanderlinden; Els Vanstreels; Eline Boons; Wouter ter Veer; Anke Huckriede; Dirk Daelemans; Alfons Van Lommel; Erzsébet Rőth; Ferenc Sztaricskai; Pàl Herczegh; Lieve Naesens
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

4.  Protective efficacy of a sulfated sialyl lipid (NMSO3) against human rotavirus-induced diarrhea in a mouse model.

Authors:  Kazuo Takahashi; Kazutaka Ohashi; Yurika Abe; Shuichi Mori; Koki Taniguchi; Takusaburo Ebina; Osamu Nakagomi; Masaki Terada; Shiro Shigeta
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 5.  Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.

Authors:  Kerry M Empey; R Stokes Peebles; Jay K Kolls
Journal:  Clin Infect Dis       Date:  2010-05-01       Impact factor: 9.079

Review 6.  Targeting RSV with vaccines and small molecule drugs.

Authors:  Heather M Costello; William C Ray; Supranee Chaiwatpongsakorn; Mark E Peeples
Journal:  Infect Disord Drug Targets       Date:  2012-04

7.  RhoA-derived peptide dimers share mechanistic properties with other polyanionic inhibitors of respiratory syncytial virus (RSV), including disruption of viral attachment and dependence on RSV G.

Authors:  Philip J Budge; Yeqiang Li; Judy A Beeler; Barney S Graham
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Orally active fusion inhibitor of respiratory syncytial virus.

Authors:  Christopher Cianci; Kuo-Long Yu; Keith Combrink; Ny Sin; Bradley Pearce; Alan Wang; Rita Civiello; Stacey Voss; Guangxiang Luo; Kathy Kadow; Eugene V Genovesi; Brian Venables; Hatice Gulgeze; Ashok Trehan; Jennifer James; Lucinda Lamb; Ivette Medina; Julia Roach; Zheng Yang; Lisa Zadjura; Richard Colonno; Junius Clark; Nicholas Meanwell; Mark Krystal
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

9.  Effect of NMSO3 treatment in a murine model of human metapneumovirus infection.

Authors:  Leanne Spetch; Terry L Bowlin; Antonella Casola
Journal:  J Gen Virol       Date:  2008-11       Impact factor: 3.891

Review 10.  The infectious march: the complex interaction between microbes and the immune system in asthma.

Authors:  Terianne Wong; Gary Hellermann; Shyam Mohapatra
Journal:  Immunol Allergy Clin North Am       Date:  2010-11       Impact factor: 3.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.